Sandoz Delysid (LSD 25)  D-lysergic acid diethylamide tartrate|
Sugar-coated tablets containing 0.025 mg. (25 ug.)   Ampoules of 1 ml. containing 0.1 mg. (100 ug.) for oral administration.
The solution may also be injected s.c. or i.v. The effect is identical with that of oral administration but sets in more rapidly.
INDICATIONS AND DOSAGE
a) Analytical psychotherapy, to elicit release of repressed material and provide mental relaxation, particularly in anxiety states and obsessional neuroses. The initial dose is 25 ug. (1/4 of an ampoule or 1 tablet). This dose is increased at each treatment by 25 ug. until the optimum dose (usually between 50 and 200 ug.) is found. The individual treatments are best given at intervals of one week.
b) Experimental studies on the nature of psychoses: By taking Delysid himself, the psychiatrist is able to gain an insight in the world of ideas and sensations of mental patients. Delysid can also be used to induce model psychoses of short duration in normal subjects, thus facilitating studies on the pathogenesis of mental disease.
In normal subjects, doses of 25 to 75 ug. are generally sufficient to produce a hallucinatory psychosis (on an average 1 ug./kg. body weight). In certain forms of psychosis and in chronic alcoholism, higher doses are necessary (2 to 4 ug./kg. body weight).
ANTIDOTE ~ The mental effects of Delysid can be rapidly reversed by the i.m. administration of 50 mg. chlorpromazine.
Suggestions for further reading:
Abramson HA. The Use of LSD-25 in the Therapy of Children. J Asthma Res. 1967; 5: 139-143.
Arendsenhein GW. Treatment of the Neurotic Patient, Resistant to the Usual Techniques of Psychotherapy, with Special Reference to LSD. Top Probl Psychother. 1963;10:50-7.
Ball JR, Armstrong JJ. The use of L.S.D. 25 in the treatment of the sexual perversions. Can Psychiatr Assoc J. 1961 Aug;6:231-5.
Chandler A.L., Hartman M.A. Lysergic Acid Diethylamide (LSD-25) as a Facilitating Agent in Psychotherapy. AMA Arch Gen Psych. 1960;2(3):286-299.
Chewelos N, Blewett DB, Smith CM, Hofer A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol. 1959 Sep;20:577-90.
Fisher G. Treatment of Childhood Schizophrenia Utilizing LSD and Psilocybin. MAPS Newsletter, Vol 3, Summery 1997, 18-25.
Freedman AM, Ebin EV, Wilson EA. Autistic schizophrenic children. An experiment in the use of d-lysergic acid diethylamide (LSD-25). Arch Gen Psychiatry. 1962 Mar;6:203-13.
Geert-Joergensen E, Hertz M, Knudsen K, Kristensen K. LSD-treatment. Experience gained within a three-year period. Acta Psychiatr Scand. 1964;40:SUPPL 180:373+.
Kristensen KK. LSD-Treatment Combined with Parenteral Ritalin Treatment. [LSD-behandLing kombineret med parenteral RitalinbehandLing.] Nord Psykiatr Tidsskr. 1962;16:111-6. (Danish.)
Ling T, Buckman J. The treatment of frigidity with LSD and Ritalin. Psychedelic Rev.. 1964;1:450-8.
MacLean JR, MacDonald DC, Byrne UP, Hubbard AM. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol. 1961 Mar;22:34-45.
Pos R. LSD-25 as an adjunct to long-term psychotherapy. Can Psychiatr Assoc J. 1966 Aug;11(4):330-42.
Sandison RA, Spencer AM, Whitelaw JDA. The therapeutic value of lysergic acid diethylamide in mental illness. J. Ment. Sci.. 1954;100:491.
Schmiege GR Jr. LSD as a Therapeutic Tool. J Med Soc N J. 1963 May;60:203-7.
Taylor GC. An analysis of the problems presented in the use of LSD. Bull Narcot. 1967 Jan.-Mar.
Tenenbaum B. Group therapy with LSD-25. (A preliminary report). Dis Nerv Syst. 1961 Aug;22:459-62.